There was a pump up of the share price( and some who actually believed Insmed should be worth a half billion dollars for an Orphan drug.
Thats right kids! bigger money than you played to your sentiment of 30 dollars soon ! We're going Higher!
Some of the names of these shorts were ...Leerink Swann,Lazard Capital and Canaccord Genuity Inc. . ...you dont think they knew the positioning of the offering? Its business as usual for the naive inexperienced biotech investor.No matter how many times they pick your pocket- the response is the same- manipulation! NO CHT